updated 2/17/2011 7:16:25 AM ET 2011-02-17T12:16:25

DENVER, Feb. 17, 2011 (GLOBE NEWSWIRE) -- MusclePharm Corporation, a Nevada corporation ("MusclePharm" or the "Company") (OTCBB:MSLP), an expanding U.S. nutritional supplement company, is pleased to announce that James Sapirstein has joined the MusclePharm team as a strategic advisor in the HIV/AIDS market for its therapeutic nutritional products, MuscleGel and Re-con.

Mr. Sapirstein is the former President and Chief Executive Officer of Tobira Therapeutics, Inc., a New Jersey-based biopharmaceutical company that develops novel compounds for HIV/AIDS ("Tobira"), and brings a wealth of experience and expertise to MusclePharm's advisory board. He has more than 27 years of pharmaceutical experience, 22 of which have a specialty focus in infectious diseases.

"James adds an impressive level of leadership on the business side and his track record speaks for itself," MusclePharm President Cory Gregory said. "From launching products to the infrastructure and intricacies of a successful pharmaceutical company, James has a tremendous amount of experience in this field and he is a terrific addition to the MusclePharm team."

Gregory added, "We are excited to have another talented person on our advisory board and it is another positive step towards helping two of our new products, Re-con and MuscleGel, to receive designation for public health program reimbursement."

Prior to his time at Tobira, Sapirstein served as the Executive Vice President of the metabolic and endocrinology business unit at Serono, Inc. ("Serono"), where he rebuilt a struggling HIV/AIDS franchise and boosted its pediatric growth hormone business.

In his position at Serono, Sapirstein, who holds a pharmacy degree from Rutgers University and Master's Degree from Farleigh Dickinson University, led a team of more than 100 people that commercialized Serostim®, Saizen® and Zorbtive® in the United States.

About MusclePharm Corporation

Headquartered in Denver, Colorado, MusclePharm is a healthy life-style company that develops and manufactures a full line of National Science Foundation approved nutritional supplements that are 100% free of banned substances. Based on years of research, MusclePharm products are created through an advanced six-stage research protocol involving the expertise of top nutritional scientists and field tested by more than one hundred elite professional athletes from various professional sports leagues including the National Football League, Mixed Martial Arts, and Major League Baseball. The Company's products address all categories of an active lifestyle, including muscle building, weight loss, and maintaining general fitness through a daily nutritional supplement regimen. MusclePharm is sold in over 120 countries and available in over 5,000 U.S. retail outlets, including GNC and Vitamin Shoppe. MusclePharm products are also sold in over 100 online stores, including bodybuilding.com, Amazon.com and Vitacost.com. For more information, please visit www.musclepharm.com.

Forward Looking Statements

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

CONTACT: Investor Contact:
         Cory Gregory,

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com